GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vertex Pharmaceuticals Inc (NAS:VRTX) » Definitions » Degree of Operating Leverage

VRTX (Vertex Pharmaceuticals) Degree of Operating Leverage : -11.78 (As of Mar. 2025)


View and export this data going back to 1991. Start your Free Trial

What is Vertex Pharmaceuticals Degree of Operating Leverage?

Degree of Operating Leverage (DOL) measures the percentage change in EBIT for a unit change in Revenue. Vertex Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 was -11.78. The higher Degree of Operating Leverage, the higher operating risk the company will take.

The industry rank for Vertex Pharmaceuticals's Degree of Operating Leverage or its related term are showing as below:

VRTX's Degree of Operating Leverage is ranked better than
92.61% of 880 companies
in the Biotechnology industry
Industry Median: -0.02 vs VRTX: -11.78

Vertex Pharmaceuticals Degree of Operating Leverage Historical Data

The historical data trend for Vertex Pharmaceuticals's Degree of Operating Leverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vertex Pharmaceuticals Degree of Operating Leverage Chart

Vertex Pharmaceuticals Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Degree of Operating Leverage
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.41 -0.55 2.99 0.30 -8.03

Vertex Pharmaceuticals Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Degree of Operating Leverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.32 -10.75 -9.26 -8.03 -11.78

Competitive Comparison of Vertex Pharmaceuticals's Degree of Operating Leverage

For the Biotechnology subindustry, Vertex Pharmaceuticals's Degree of Operating Leverage, along with its competitors' market caps and Degree of Operating Leverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vertex Pharmaceuticals's Degree of Operating Leverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vertex Pharmaceuticals's Degree of Operating Leverage distribution charts can be found below:

* The bar in red indicates where Vertex Pharmaceuticals's Degree of Operating Leverage falls into.


;
;

Vertex Pharmaceuticals Degree of Operating Leverage Calculation

Vertex Pharmaceuticals's Degree of Operating Leverage for the quarter that ended in Mar. 2025 is calculated as:

Degree of Operating Leverage=% Change in EBIT**/% Change in Revenue
=( -277 (Mar. 2025) / 4810.5 (Mar. 2024) - 1 )/( 11099.7 (Mar. 2025) / 10185 (Mar. 2024) - 1 )
=-1.0576/0.0898
=-11.78***

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** TTM data of EBIT and Revenue was used to calculate Degree of Operating Leverage.
*** Please be aware that the Degree of Operating Leverage calculations are based on company-level data using the primary share class. The calculated data provided is for demonstration purposes and may slightly differ from the results displayed in the title due to potential variations caused by currency exchange rate differences throughout the year.


Vertex Pharmaceuticals  (NAS:VRTX) Degree of Operating Leverage Explanation

Degree of Operating Leverage (DOL) is a leverage ratio that measures the sensitivity of a company’s operting income, also referred to as Earnings Before Interest and Taxes (EBIT), to fluctuations in its Revenue. DOL is a method used to quantify a company’s operating risk. This risk is related to the company's structure of variable costs and fixed costs. Since the fixed costs do not allow the company to adjust the operating costs, the operating risk rises with a higher fixed-to-variable costs proportion.

A high Degree of Operating Leverage indicates that the company’s fixed costs exceed its variable costs. By increasing the sales, the company can earn more profits. In addition, the company must be able to maintain relatively high sales to cover all fixed costs.

Be Aware

The use of operating leverage varies across different industries and business sectors, and the application of Degree of Operating Leverage (DOL) should be adjusted accordingly.


Vertex Pharmaceuticals Degree of Operating Leverage Related Terms

Thank you for viewing the detailed overview of Vertex Pharmaceuticals's Degree of Operating Leverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Vertex Pharmaceuticals Business Description

Address
50 Northern Avenue, Boston, MA, USA, 02210
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Executives
David Altshuler officer: EVP, Global Research and CSO C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Sangeeta N. Bhatia director C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Ourania Tatsis officer: EVP, Chief Reg. & Quality Off. C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Wagner Charles F Jr officer: EVP & Chief Financial Officer C/O MILLIPORE CORP, BILLERICA MA 01820
Atkinson Edward Morrow Iii officer: EVP, Chief Technical Ops. Off. C/O 89BIO, INC., 142 SANSOME STREET, SECOND FLOOR, SAN FRANCISCO CA 94104
Kristen Ambrose officer: SVP & Chief Accounting Officer C/O VERTEX PHARMACEUTICALS INCORPORATED, 50 NORTHERN AVENUE, BOSTON MA 02210
Jonathan Biller officer: EVP and Chief Legal Officer C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901
Reshma Kewalramani director, officer: CEO & President C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Jeffrey M Leiden director 15 N BEACH ROAD, HOBE SOUND FL 33455
Carmen Bozic officer: EVP and CMO C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Bruce I Sachs director C/O VERTEX PHARMACEUTICALS, INC., 50 NORTHERN AVENUE, BOSTON MA 02210
Stuart A Arbuckle officer: EVP, COO VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY ST., CAMBRIDGE MA 02139
Amit Sachdev officer: SVP, Public Policy,Gov Affairs C/O VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Michel Lagarde director 450 LEXINGTON AVE., 31ST FLOOR, NEW YORK NY 10017
Terrence C Kearney director IN CARE OF HOSPIRA, INC., 275 NORTH FIELD DRIVE, LAKE FOREST IL 60045